Journal article
Beyond Alzheimer's disease-translating biomarker insights across CNS diseases
Science translational medicine, Vol.17(823), eadr2511
11/05/2025
DOI: 10.1126/scitranslmed.adr2511
PMCID: PMC13162155
PMID: 41191776
Abstract
Decades of research on biomarker identification and integration in Alzheimer's disease (AD) have helped to advance biologically driven disease models, disease subtypes, and disease-modifying treatments. Key lessons learned from AD biomarker development include the need for integration of new biological insights, investment in large cross-sectional and longitudinal studies, a multicomponent biomarker approach, and recruitment of clinical trial cohorts and biosamples that are representative of the target population. We describe how these lessons are being applied in Parkinson's disease, Huntington's disease, multiple sclerosis, and psychotic disorders as use cases to inform biomarker-based approaches across central nervous system disorders.
Details
- Title: Subtitle
- Beyond Alzheimer's disease-translating biomarker insights across CNS diseases
- Creators
- Linda S Brady - National Institute of Mental HealthSimin Mahinrad - Alzheimer's AssociationRebecca M Edelmayer - Alzheimer's AssociationWilliam Z Potter - Philadelphia UniversitySamantha J Hutten - Michael J. Fox FoundationAlan Anticevic - Yale UniversityCarol Taylor-Burds - National Institute of Neurological Disorders and StrokeCharisse N Winston - University of Southern CaliforniaTimothy Coetzee - National Multiple Sclerosis SocietyJane S Paulsen - University of Wisconsin–MadisonValentina Mantua - United States Food and Drug AdministrationEva P Childers - National Academies of Sciences, Engineering, and MedicineHartmuth C Kolb - Enigma Biomedical Group, Knoxville, TN 37922, USAClifford R Jack Jr - Mayo ClinicWilliam J Jagust - University of California, BerkeleyJohn A Wagner - Temper (United States)Sudhir Sivakumaran - Lewy Body Dementia Association Inc., Lilburn, GA 30047, USALeslie Shaw - University of PennsylvaniaVikas Mohan Sharma - Neuraxpharm (Spain)
- Resource Type
- Journal article
- Publication Details
- Science translational medicine, Vol.17(823), eadr2511
- DOI
- 10.1126/scitranslmed.adr2511
- PMID
- 41191776
- PMCID
- PMC13162155
- NLM abbreviation
- Sci Transl Med
- ISSN
- 1946-6242
- eISSN
- 1946-6242
- Publisher
- AAAS; WASHINGTON
- Grant note
- NIH: U01FD008399 National Institute on AgingDepartment of DefenseFujirebioMichael J. Fox Foundation for Parkinson's Research
Research funding from the NIH grant nos. U01NS103475, U01NS105509, RF1AG074608, R01AG082208, R01AG085602, and R01AG082174 (to J.S.P.); National Institute on Aging (to W.J.J.); NIH (to L.S.); FDA grant no. U01FD008399 (to J.S.P.); Department of Defense (to L.S.); Roche (to L.S.); Fujirebio (to L.S.); and Michael J. Fox Foundation for Parkinson's Research (to L.S.). All other authors declare that no funding supported this Review.
- Language
- English
- Date published
- 11/05/2025
- Academic Unit
- Psychiatry
- Record Identifier
- 9985024144202771
Metrics
13 Record Views